



CUPID LIMITED

Manufacturer & Exporter of Male Condoms, Female Condoms,
Water based Lubricants & In Vitro Diagnostics (IVD) Kits

We Help The World Play Safe

Date: 18th October, 2025

To,

Department of Corporate Services,

BSE LIMITED,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

SCRIP CODE: 530843

The National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor, Bandra-Kurla

Complex, Bandra (East),

Mumbai - 400051

Fax No. – 6641 8125 / 26

SCRIP CODE: CUPID

**Subject: - Press Release – Cupid Limited Achieves CE (EU IVDR) Certification for
Pregnancy and Syphilis Test Kits**

Dear Sir / Madam,

With reference to the captioned subject, enclosed herewith the press release on Cupid Limited Achieves CE (EU IVDR) Certification for Pregnancy and Syphilis Test Kits.

The above is for your information and dissemination to the stakeholders.

Thanking you.

For Cupid Limited

Saurabh V. Karmase

Company Secretary and Compliance Officer

Factory & Registered Office:

CIN No.: L25193MH1993PLC070846



A-68, M.I.D.C. (Malegaon), Sinnar,
Nashik - 422113, Maharashtra, India



+91 2551 230280 / 230772
+91 7722009580



www.cupidlimited.com
info@cupidlimited.com



Cupid Limited Achieves CE (EU IVDR) Certification for Pregnancy and Syphilis Test Kits — Paving the Way for Global Expansion in the Multi-Billion US Dollar IVD Market

Mumbai, October 18, 2025 – Cupid Limited, (BSE – 530843, NSE – CUPID), Cupid Limited, a leading Indian healthcare and diagnostics manufacturer, announced today that it has been granted CE (EU IVDR) Certification for two of its key in-vitro diagnostic (IVD) devices — the CupiSURE Pregnancy (hCG) Test Kit and the CupiKIT Syphilis Antibody Test Kit.

These certifications confirm compliance with the European Union Regulation (EU) 2017/746 (IVDR), authorizing Cupid to distribute these kits across the European Economic Area and other CE-recognized global markets. The development marks a major step in Cupid's transition from an Indian healthcare exporter to a globally certified IVD solutions provider.

Strong Global Market Outlook

Cupid's certified IVD kits target two of the fastest-growing diagnostic categories:

Pregnancy (hCG) Test Kits — Global market valued at USD 1.7 billion in 2024, projected to reach USD 2.9 billion by 2034 (CAGR ~5.4%).

Syphilis Immunoassay Diagnostics — Estimated at USD 611 million in 2025, expected to grow to USD 993 million by 2034 (CAGR ~5.6%).

In addition, Cupid is in the final stages of securing CE (EU IVDR) Certification for its HIV 1 & 2 Antibody and Hepatitis B Antigen IVD kits, expected by December 2025 — products that address some of the world's largest and most urgent diagnostic markets:

HIV 1 & 2 Antibody Diagnostics — Global market estimated at USD 3.6 billion in 2025, projected to expand to USD 6.1 billion by 2030 (CAGR ~10.7%).

Hepatitis B Antigen IVD Diagnostics — Valued at USD 1.3 billion in 2024, expected to surpass USD 2.0 billion by 2033 (CAGR ~4.2%).

Collectively, these four segments represent a vast global market opportunity, offering substantial room for Cupid's expansion in both public health and private clinical sectors.

Strategic Significance for Cupid Ltd.

With these CE (EU IVDR) approvals, Cupid can now:

Participate in European, African, and Latin American tenders for maternal health, STD, and infectious-disease screening.

Leverage its low-cost, high-quality manufacturing base in India to deliver competitively priced global IVD solutions.

The certifications also reinforce Cupid's commitment to diversifying beyond sexual-health products into the broader preventive and diagnostic healthcare space, aligning with the global shift toward early detection and rapid testing.

Commenting on the development, Mr. Aditya Kumar Halwasiya, Chairman and Managing Director said, "The CE (EU IVDR) Certification for our Pregnancy and Syphilis Antibody IVD kits is a milestone achievement that validates Cupid's global quality standards and technical excellence. These certifications open up huge opportunities for us across Europe, Africa, and Asia. With HIV 1&2 Antibody and Hepatitis B Antigen kits on track for approval by December 2025, Cupid is poised to become one of India's few integrated diagnostic companies with a globally certified product suite. We aim to build a strong international footprint and make accurate, affordable diagnostics accessible to all."

About Cupid Limited

Established in 1993, CUPID Limited, India's premier manufacturer and brand of male and female condoms, water based personal lubricants, IVD kits, deodorants, perfumes, almond hair oil, body oils, petroleum jelly and other FMCG Products. The company operates with a strong commitment to public health and well-being, maintaining ethical business practices aligned with international standards.

In alignment with its strategic growth plans, the company has recently expanded its product offerings to include Fast-Moving Consumer Goods (FMCG) such as fragrance products (Eau De Perfumes, Deodorants, Pocket Perfumes), personal care items (Toilet Sanitizers, Hair & Body Oils, Hair Removal Sprays, Face Wash), and other wellness solutions.

In March 2024, the company completed a strategic land acquisition in Palava, Maharashtra, enabling it to amplify its production capacity by 1.5 times the existing output. As a result, the annual production capacity will be augmented by approximately 770 million male condoms and 75 million female condoms.

The company has a prominent presence in international markets and is the first company in the world to attain WHO / UNFPA pre-qualification for both male and female condoms.

CUPID currently exports its products to over 110 countries, with a substantial portion of its revenue generated from international markets. Furthermore, CUPID has established a long-term agreement with WHO / UNFPA. The company is listed on BSE (BSE: 530843) and NSE (NSE: CUPID).

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any

action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor



Kirin Advisors Private Limited

Sunil Mudgal – Director

sunil@kirinadvisors.com

+91 98692 75849

www.kirinadvisors.com